Clinical Trials
27 trialsA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
Zhejiang University
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
The General Hospital of Western Theater Command
Allogeneic UCB-derived CAR-T for B-ALL
The General Hospital of Western Theater Command
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Guangzhou Bio-gene Technology Co., Ltd
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Thomas Jefferson University
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
Zhejiang University
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
The First Affiliated Hospital of Soochow University
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
Anhui Provincial Hospital
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Hrain Biotechnology Co., Ltd.
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Hebei Yanda Ludaopei Hospital
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Northwestern University
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Hebei Yanda Ludaopei Hospital
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)
Shanghai Longyao Biotechnology Inc., Ltd.
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma
M.D. Anderson Cancer Center
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Hebei Yanda Ludaopei Hospital
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Case Comprehensive Cancer Center